Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 26;2021:2958584. doi: 10.1155/2021/2958584

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Kaiqiang Sun et al.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Novel CGRP receptor antagonist, Rimegepant, could ameliorate CGRP-mediated apoptosis and ECM degradation in vitro. (a) Rimegepant concentration screening was carried out using CCK 8 assay, and the results showed that Rimegepant less than 10 μM is nontoxic to human NP cells. (b) Rimegepant could restore CGRP-mediated decreased cell viability in human NP cells. (c, d) TUNEL assay revealed that TUNEL-positive NP cells were increased significantly in the CGRP group, whereas human NP cells treated with CGRP plus Rimegepant showed decreased TUNEL-positive NP cells compared to the control group. (e, f) Immunofluorescence analysis suggested less protein translation of aggrecan and higher protein translation of MMP 3 in CGRP-treated human NP cells. However, Rimegepant could reverse these effects. ^∗^/#p < 0.05, ^∗∗^/##p < 0.01, ^∗∗∗^/###p < 0.001, and ^∗∗∗∗^/####p < 0.0001; ns: no significance. Scale bar = 100 μm.